Zacks Research Has Positive Outlook for Novavax Q2 Earnings

Posted by Stanley Muller on May 27th, 2026

Novavax, Inc. (NASDAQ:NVAX – Free Report) – Zacks Research lifted their Q2 2026 earnings estimates for Novavax in a research report issued to clients and investors on Friday, May 22nd. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.29). The consensus estimate for Novavax’s current full-year earnings is ($0.20) per share. Zacks Research also issued estimates for Novavax’s Q4 2026 earnings at $0.29 EPS, FY2026 earnings at $0.03 EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at $0.08 EPS, FY2027 earnings at $0.01 EPS, Q1 2028 earnings at $0.06 EPS and FY2028 earnings at $1.29 EPS.

Novavax (NASDAQ:NVAX – Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The company had revenue of $118.90 million during the quarter, compared to the consensus estimate of $79.81 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.Novavax’s quarterly revenue was down 79.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.93 earnings per share.

NVAX has been the subject of several other research reports. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright boosted their target price on shares of Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, February 27th. B. Riley Financial restated a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Weiss Ratings cut Novavax from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novavax has a consensus rating of “Hold” and a consensus price target of $12.13.

View Our Latest Stock Report on Novavax

Novavax Price Performance

NASDAQ:NVAX opened at $10.46 on Wednesday. Novavax has a 12-month low of $6.13 and a 12-month high of $11.97. The business has a 50 day simple moving average of $8.83 and a 200 day simple moving average of $8.30. The firm has a market capitalization of $1.72 billion, a P/E ratio of -18.03 and a beta of 2.37.

Hedge Funds Weigh In On Novavax

Hedge funds have recently modified their holdings of the company. Shah Capital Management raised its stake in shares of Novavax by 23.3% in the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock worth $97,835,000 after buying an additional 2,747,000 shares in the last quarter. State Street Corp grew its holdings in Novavax by 32.3% during the fourth quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after acquiring an additional 2,326,927 shares during the period. UBS Group AG grew its holdings in Novavax by 40.3% during the fourth quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock worth $32,890,000 after acquiring an additional 1,405,981 shares during the period. Allianz Asset Management GmbH raised its position in Novavax by 162.6% in the third quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock worth $12,222,000 after acquiring an additional 872,987 shares in the last quarter. Finally, Farallon Capital Management LLC raised its position in Novavax by 4,775.0% in the third quarter. Farallon Capital Management LLC now owns 780,000 shares of the biopharmaceutical company’s stock worth $6,763,000 after acquiring an additional 764,000 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

(Get Free Report)

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.